Understanding Medications for Idiopathic Pulmonary Fibrosis (IPF)
Managing idiopathic pulmonary fibrosis (IPF) requires a strategic approach to medication. Because IPF causes progressive scarring of the lung tissue, treatment isn’t about a cure, but rather a two-pronged strategy: slowing the progression of the disease and managing the symptoms that impact daily quality of life.
- Antifibrotics are the primary medications used to slow lung scarring and preserve function.
- Corticosteroids are generally reserved for short-term use during acute exacerbations (flare-ups).
- Supportive therapies, including acid reflux medications and cough suppressants, target specific symptoms rather than the underlying fibrosis.
- Early intervention with antifibrotics is often recommended following diagnosis.
Antifibrotic Medications: Slowing the Progression
Antifibrotics are the cornerstone of IPF treatment. According to Guillermo Garrido, MD, a board-certified physician with Orlando Health Medical Group Pulmonary and Sleep Medicine, there are currently three FDA-approved options. It’s important to understand that these drugs do not reverse existing scarring; instead, they slow the rate at which the lungs build new scar tissue to help preserve lung function over time.
Because of their ability to protect lung function, these medications are typically started at or shortly after diagnosis.
Approved Antifibrotic Options
- Nintedanib (Ofev)
- Pirfenidone (Esbriet)
- Nerandomilast (Jascayd): Approved by the FDA in 2025, this is the first new treatment for IPF in over a decade. It utilizes a different mechanism than the other two options and is often used as an alternative for patients who cannot tolerate nintedanib or pirfenidone.
Managing Side Effects
All three antifibrotics are taken orally, but they can cause side effects. Your healthcare team will monitor your response and may adjust dosages to manage the following:
- Nausea, vomiting, or diarrhea
- Loss of appetite or weight loss
- Elevated liver enzymes
- Fatigue, headache, or dizziness
- Skin Sensitivity: Patients taking pirfenidone may experience skin rashes or increased sun sensitivity, making sun protection essential.
Corticosteroids for Acute Exacerbations
While antifibrotics provide long-term management, corticosteroids (steroids) are used for short-term intervention. These are typically prescribed during “flare-ups,” known as acute exacerbations, to reduce lung inflammation and relieve immediate symptoms.
Commonly used steroids include prednisone (Deltasone, Predone, Sterapred) and methylprednisolone (Medrol). Because evidence on their ability to improve long-term outcomes is limited, they are generally not used for chronic maintenance.
Potential side effects of steroids include:
- Weight gain and swelling in the midsection or legs
- High blood pressure and elevated blood sugar levels
- Insomnia and trouble sleeping
- Mood changes, including anxiety or irritability
- Increased susceptibility to infections
- Upset stomach
Managing Comorbidities and Symptoms
IPF often comes with secondary conditions or frustrating symptoms that require their own medication strategies. While these treatments don’t stop the fibrosis, they are vital for patient comfort.
Acid Reflux (GERD) Management
Many people with IPF also struggle with gastroesophageal reflux disease (GERD). When stomach acid flows back into the esophagus, it can be inhaled into the lungs, irritating lung tissue and worsening shortness of breath or coughing.
Medications such as omeprazole (Prilosec), esomeprazole (Nexium), and famotidine (Pepcid) work by reducing or blocking acid production. It is critical to note that these medications manage GERD symptoms to prevent further lung irritation; they do not treat the IPF itself.
Controlling the Persistent Cough
A dry, persistent cough is one of the most challenging symptoms of IPF and often resists standard over-the-counter treatments. Depending on the patient’s specific needs, doctors may prescribe:
- Dextromethorphan (Delsym, Robitussin)
- Benzonatate (Tessalon Perles)
Comparing IPF Medication Types
| Medication Class | Primary Goal | Example Drugs |
|---|---|---|
| Antifibrotics | Slow lung scarring & preserve function | Nintedanib, Pirfenidone, Nerandomilast |
| Corticosteroids | Reduce inflammation during flare-ups | Prednisone, Methylprednisolone |
| GERD Medications | Prevent acid inhalation into lungs | Omeprazole, Famotidine |
| Cough Suppressants | Relieve persistent dry cough | Benzonatate, Dextromethorphan |
Looking Ahead
The landscape of IPF treatment is evolving, as evidenced by the 2025 approval of nerandomilast. As research continues into different mechanisms of action, the goal remains to provide patients with a broader toolkit to slow disease progression and maintain a higher quality of life. Always consult your healthcare team to determine which combination of medications is appropriate for your specific diagnosis and health history.